山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (7): 55-60.doi: 10.6040/j.issn.1671-7554.0.2019.475
• 基础医学 • 上一篇
艾正琳1,洪珊1,胡居龙1,李坪1,周玉玲1,梁秀霞1,姚树坤2
AI Zhenglin1, HONG Shan1, HU Julong1, LI Ping1, ZHOU Yuling1, LIANG Xiuxia1, YAO Shukun2
摘要: 目的 观察黄芩苷对非酒精性脂肪性肝炎(NASH)的治疗效果及其抗炎疗效。 方法 采用高脂饮食诱导建立大鼠NASH模型,给予不同剂量的黄芩苷(15 、30、60 mg/kg·d)治疗后,测定大鼠肝质量及体质量变化,苏木精-伊红(HE)染色观察肝组织病理学变化,并测定血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)水平,比色法测定肝组织超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)酶活性及丙二醛(MDA)含量变化,酶联免疫吸附(ELASA)测定肝组织肿瘤坏死因子α(TNFα)、白介素-6(IL-6)、白介素-1β(IL-1β)含量变化。 结果 经黄芩苷治疗后,NASH大鼠的体质量及肝质量减轻(F=1609.79, P<0.001;F=155.17, P<0.001),二指标随剂量增加而下降。经不同剂量黄芩苷治疗后,病理学可见肝细胞脂肪变性逐渐减轻,小叶间炎性细胞浸润逐渐减少。治疗后,血清ALT和AST减少(F=177.16,P<0.001;F=2 998.11,P<0.001),随剂量增加而减少。而肝脏GSH、SOD酶活性经黄芩苷治疗后增加(F=398.47,P<0.001;F=256.07,P<0.001),随治疗浓度增加而增加。肝组织MDA的变化则相反(F=237.98,P<0.001),随治疗浓度增加而下降。肝组织TNFα、IL-1β、IL-6含量经黄芩苷治疗后均降低(F=399.15,P<0.001;F=314.76,P<0.001;F=108.38,P<0.001),三者随治疗浓度增加而下降。 结论 黄芩苷能减轻NASH大鼠的脂肪变性程度,通过增加GSH、SOD酶的活性,减少TNFα、IL-1β、IL-6炎性因子的产生,缓解肝脏的炎症,发挥其抗炎作用。
中图分类号:
[1] Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives [J]. J Gastroenterol, 2017, 52(2): 164-174. [2] Xu ZJ, Shi JP, Yu DR, et al. Evaluating the relationship between metabolic syndrome and liver biopsy-proven non-alcoholic steatohepatitis in China: a multicenter cross-sectional study design [J]. Adv Ther, 2016, 33(11): 2069-2081. [3] Younossi ZM, Korenning AB, Adelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes [J]. Hepatology, 2016, 64(1): 73-84. [4] Sanyal AJ, Harrison SA, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials [J]. Hepatology, 2019, 16. doi: 10.1002/hep.30664. [5] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia [J]. J Hepatol, 2017, 67(4): 862-873. [6] Polyzos SA, Kountouras J, Mantaoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics [J]. Metabolism, 2019, 92: 82-97. doi: 10.1016/j.metabol.2018.11.014. [7] Yang J, Fernández-Galilea M, Martínez-Fernández L, et al. Oxidative stress and non-alcoholic fatty liver disease: effects of omega-3 fatty acid supplementation [J]. Nutrients, 2019,18,11(4): 872. doi: 10.3390/nu11040872. [8] Chirumbolo S. Baicalin in flavocoxid may act against hepatitis B virus via a pro-inflammatory pathway [J]. Inflamm Res, 2018, 67(3): 203-205. [9] Zhang J, Zhang H, Deng X, et al. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice [J]. Life Sci, 2018, 192: 46-54. doi: 10.1016/j.lfs.2017.11.027. [10] He P, Wu Y, Shun J, et al. Baicalin ameliorates liver injury induced by chronic plus binge ethanol feeding by modulating oxidative stress and inflammation via CYP2E1 and NRF2 in mice [J]. Oxid Med Cell Longev, 2017, 2017:4820414. doi: 10.1155/2017/4820414. [11] 艾正琳, 张伟硕, 姚树坤, 等. 黄芩苷对体外氧化应激模型中肝型脂肪酸结合蛋白表达的影响及意义[J]. 中华肝脏病杂志, 2011, 19(12): 53-57. AI Zhenglin, ZHANG Weishuo, YAO Shunkun, et al. Effect of baicalin on liver fatty acid binding protein in oxidative stress in vitro[J]. Chinese Jounal of Hepatology, 2011, 19(12): 53-57. [12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 18(3): 163-166. The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease for the Liver Disease Association. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition [J]. Chinese Jounal of Hepatology, 2010, 18(3): 163-166. [13] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病诊疗指南(2018更新版)[J]. 中华肝脏病杂志, 2018, 26(3): 195-203. [14] Lieber CS, Leo MA, Mak KM, et al. Model of nonalcoholic steatohepatitis [J]. Am J Clin Nutr, 2004, 79(3): 502-509. [15] Sunaram V, Morgan TR. Will studies in nonalcoholic steatohepatitis help manage alcoholic steatohepatitis? [J]. Clin Liver Dis, 2019, 23(1): 157-165. [16] Farzanegi P, Dana A, Ebrahimpoor Z, et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease(NAFLD): Roles of oxidative stress and inflammation [J]. Eur J Sport Sci, 2019, 19(7): 994-1003. [17] Chen K, Ma J, Jia X, et al. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans [J]. Biochim Biophys Acta Rev Cancer, 2019, 1871(1): 117-125. [18] Liang Q, Chen H, Xu X, et al. miR-182-5p Attenuates high-fat -diet-induced nonalcoholic steatohepatitis in mice [J]. Ann Hepatol. 2019, 18(1): 116-125. [19] Jia R, Du J, Cao L,et al. Antioxidative, inflammatory and immune responses in hydrogen peroxide-induced liver injury of tilapia(GIFT, Oreochromis niloticus)[J]. Fish Shellfish Immunol, 2018, 31(84): 894-905. [20] Uchio R, Murosaki S, Ichikawa H. Hot water extract of turmeric(Curcuma longa)prevents non-alcoholic steatohepatitis in mice by inhibiting hepatic oxidative stress and inflammation [J]. J Nutr Sci, 2018, 27(7): 36. doi: 10.1017/jns.2018.27. eCollection 2018. [21] Sutti S, Jindal A, Locatelli I, et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH [J]. Hepatology, 2014, 59(3): 886-897. [22] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression [J]. Cell Mol Life Sci, 2019, 76(1): 99-128. [23] Chen Z, Yu R, Xiong Y, et al. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease [J]. Lipids Health Dis, 2017, 16(1): 203. doi: 10.1186/s12944-017-0572-9. [24] Henkel J, Coleman CD, Schraplau A, et al. Augmented liver inflammation in a microsomal prostaglandin E synthase 1(mPGES-1)-deficient diet-induced mouse NASH model [J]. Sci Rep, 2018, 8(1): 16127. [25] Atay K, Canbakan B, Koroglu E, et al. Apoptosis and disease severity is associated with insulin resistance in non-alcoholic fatty liver disease [J]. Acta Gastroenterol Belg, 2017, 80(2): 271-277. [26] Jorge ASB, Andrade JMO, Paraiso AF, et al. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity [J]. Obes Res Clin Pract, 2018, 12(Suppl 2): 1-8. [27] Nawaz R, Zahid S, Idrees M, et al. HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-γ operative, leading liver en-route to non-alcoholic steatohepatitis [J]. Inflamm Res, 2017, 66(6): 477-486. [28] Lambertucci F, Arboatti A, Sedlmier MG, et al. Disruption of tumor necrosis factor alpha receptor 1 signaling accelerates NAFLD progression in mice upon a high-fat diet [J]. J Nutr Biochem, 2018, 58: 17-27. doi: 10.1016/j.jnutbio.2018.04.013. [29] Nelson JE, Handa P, Aouizerat B, et al. Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms [J]. Aliment Pharmacol Ther, 2016, 44(11-12): 1253-1264. |
[1] | 李鸿皓,于晶,陈亚丽,郭守刚. 20例NMOSD患者CD4+CD25+FoxP3+调节性T细胞数量和FoxP3 mRNA的表达水平[J]. 山东大学学报 (医学版), 2022, 60(4): 50-54. |
[2] | 陈虹瑜,曲竹丽,孙琪,赵华强,马川. IL-1β介导的ERK通路对大鼠髁突软骨细胞外基质的作用[J]. 山东大学学报 (医学版), 2019, 57(5): 80-86. |
[3] | 陈欧,李国勇,刘爱红,朱晓波,陈少杰,王一彪. 网络药理学预测麻黄治疗哮喘的抗炎作用机制[J]. 山东大学学报 (医学版), 2019, 57(1): 55-61. |
[4] | 李竹青,张文雪,李理想,王鹏,于岩波,左秀丽,李延青. 丁酸钠下调IRAK1改善肠易激综合征内脏高敏感[J]. 山东大学学报 (医学版), 2018, 56(9): 23-28. |
[5] | 王波,薛江,刘爱虹,翟蕊蕊,王一彪. 雷帕霉素调控巨噬细胞表型改善肺动脉高压[J]. 山东大学学报 (医学版), 2018, 56(4): 51-57. |
[6] | 姬原原,包景泊,赵旭,曹鲁宁,崔敏,张娜,于灵芝. 白介素17F促进大鼠成骨细胞增殖、矿化和Runx2、Osterix的表达[J]. 山东大学学报(医学版), 2017, 55(8): 24-29. |
[7] | 张鹏亮,张龙腾,李爱玲,沈涛,娄红祥,王小宁. 植物内生真菌Leptosphaeria sp.中两个新氧杂蒽酮类化合物leptosphaerins H和I的分离及抗炎活性[J]. 山东大学学报(医学版), 2017, 55(11): 27-31. |
[8] | 孙鹏飞,孟晓,张凯,黎莉. 抵抗素样分子 β在动脉粥样硬化斑块稳定性中的作用[J]. 山东大学学报(医学版), 2016, 54(3): 1-4. |
[9] | 穆军,单丽娜,翟英杰,翟光喜. 黄芩苷类脂纳米囊制剂的制备及大鼠口服药物动力学[J]. 山东大学学报(医学版), 2016, 54(1): 22-28. |
[10] | 于昕, 刘晓静, 刘向群. 黄芩苷抑制ox-LDL诱导内皮细胞凋亡的作用[J]. 山东大学学报(医学版), 2015, 53(5): 5-9. |
[11] | 仇会会1,叶丽平1,温有锋2,李丹1,宋佳1. IL-6对卵巢癌细胞bcl-2、cyclinD1和VEGF表达的影响[J]. 山东大学学报(医学版), 2014, 52(6): 17-21. |
[12] | 韩文洁1,于苏国1,崔翔宇2. N-乙酰半胱氨酸对胰岛素抵抗大鼠GLP-1、IL-6表达的影响[J]. 山东大学学报(医学版), 2014, 52(6): 12-16. |
[13] | 潘家超1,2,张乐1,2, 徐琳琳3,单晓宇2,杜文军2,陈士俊2. 黑素瘤缺乏因子2诱导的固有免疫在慢性乙型肝炎发病机制中的作用[J]. 山东大学学报(医学版), 2014, 52(4): 74-79. |
[14] | 尹海鹏,刘向群,于昕,王敏. 黄芩苷对ApoE-/-小鼠动脉粥样硬化及VE-钙黏蛋白表达水平的影响[J]. 山东大学学报(医学版), 2013, 51(9): 26-30. |
[15] | 高淑春,耿大影,崔蕾,张立新,张琴冈,陈士俊. 替比夫定对慢性乙型肝炎血清IL-2和IL-6的影响[J]. 山东大学学报(医学版), 2012, 50(8): 92-95. |
|